Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in pediatric chronic spontaneous urticaria
NCT05526521Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2022
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of dupilumab in chronic spontaneous urticaria (CSU), sponsored by Sanofi. Primary endpoint: Serum Concentration of Dupilumab at 24 weeks. Started Aug 2022; status: completed.
02
Drugs
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT05526521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05526521.